Syndax Pharmaceuticals opened lower at $9.47, compared with its previous close of $9.59. In the last trading session, the stock traded between $9.30 and $9.93. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Syndax Pharmaceuticals is now worth
$ 54.10
Resulting in a loss of
$ 45.90 (45.90%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-0.05 (-0.55%)
Day High
$9.93
Day Low
$9.30
Day Open
$9.47
Prev Close
$9.59
Volume
19,34,215
1W Return
-9.01%
1M Return
-42.37%
3M Return
-53.00%
6M Return
-55.39%
1Y Return
-46.21%
Market Cap ($ Mn)
859
PE Ratio
-
PB Ratio
115.37
PEG Ratio
-
ROE
-169.76%
ROCE
-54.92%
EPS (TTM)
$-0.55
1 Week
-9.01%
1 Month
-42.37%
3 Months
-53.00%
6 Months
-55.39%
9 Months
-56.07%
Pomerantz investigates Syndax after axatilimab trial misses endpoint
Pomerantz LLP is investigating Syndax Pharmaceuticals for potential securities fraud. Axatilimab Phase 2 trial for idiopathic pulmonary fibrosis missed its primary endpoint. Syndax stock fell 2.59% to close at $16.55 following the announcement. Investors are advised to contact legal counsel regarding class action participation.
2 days agoSyndax Pharmaceuticals grants 270,000 stock options to new CFO Aaron Ondrey
Syndax Pharmaceuticals granted 270,000 stock options to new CFO Aaron A. Ondrey. The exercise price is set at $9.55 per share, matching the Nov 9, 2026 closing price. Options vest over four years with 25% cliff and monthly thereafter. Award approved under NASDAQ Listing Rule 5635(c)(4) as inducement for employment.
3 days agoPomerantz investigates Syndax over failed IPF trial claims
Pomerantz LLP is investigating Syndax Pharmaceuticals for potential securities fraud. The probe follows the failure of the MAXPIRe Phase 2 trial of axatilimab for IPF. Stock price fell $0.44, or 2.59%, to $16.55 on October 12, 2026. Investigation focuses on whether officers engaged in unlawful business practices.
9 days agoHC Wainwright lowers Syndax price target to $36, keeps Buy rating
HC Wainwright maintains a Buy rating on Syndax Pharmaceuticals. Price target reduced from $38 to $36 by analyst Andres Y. Maldonado. Rating status remains unchanged despite the lower price objective.
9 days agoSyndax faces fraud probe after axatilimab trial miss, shares fall 16.68%
Schall, Brown & Schwartz LLP investigates Syndax for securities law violations. Shares fell 15.7% after Phase 2 MAXPIRe trial missed primary endpoint. Axatilimab halted in IPF but continues in cGVHD trials. FDA-approved Niktimvo remains unaffected by IPF trial failure.
26 days agoSyndax CEO to speak at Citi and Wainwright biopharma conferences
CEO Michael Metzger to hold fireside chats at Citi and H.C. Wainwright conferences. Sessions scheduled for September 10 and 15, 2026, in New York. Live webcasts and replays will be hosted on the company website. Company continues advancing FDA-approved therapies Revuforj and Niktimvo.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Syndax Pharmaceuticals is now worth
$ 54.10
Resulting in a loss of
$ 45.90 (45.90%)
Note: Past profits do not guarantee future returns.
